Stephanie van Hoppe

118 Chapter 5 22. Stuurman, F.E., et al., Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet, 2013. 52(6): p. 399-414. 23. Sen, R., et al., The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther, 2012. 11(9): p. 2033-44. 24. Lu, L., et al., Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia, 2015. 29(8): p. 1792-4. 25. Fiere, D., et al., Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol, 1993. 11(10): p. 1990-2001. 26. Kantarjian, H.M., et al., Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol, 2000. 18(3): p. 547-61. 27. Narasimhan, N.I., et al., Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol, 2013. 53(9): p. 974-81. 28. Sparidans, R.W., et al., Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib inmouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 2016. 1023-1024: p. 24-9. 29. Durmus, S., et al., Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm, 2012. 9(11): p. 3236-45. 30. Schinkel, A.H., et al., Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug- transporting) P-glycoproteins. Proc Natl Acad Sci U S A, 1997. 94(8): p. 4028-33. 31. Jonker, J.W., et al., The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15649-54. 32. Jonker, J.W., et al., The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med, 2005. 11(2): p. 127-9. 33. vanWaterschoot, R.A., et al., Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res, 2009. 69(23): p. 8996-9002. 34. Dai, H., et al., Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther, 2003. 304(3): p. 1085-92. 35. Poller, B., et al., Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos, 2011. 39(5): p. 729-35. 36. Kort, A., et al., Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharm Res, 2015. 32(7): p. 2205-16. 37. Steinbach, D. and O. Legrand, ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia, 2007. 21(6): p. 1172-6. 38. Polli, J.W., et al., An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino }methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos, 2009. 37(2): p. 439-42. 39. Agarwal, S., et al., Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther, 2010. 334(1): p. 147-55. 40. Kodaira, H., et al., Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J Pharmacol Exp Ther, 2010. 333(3): p. 788-96. 41. Tang, S.C., et al., Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer, 2012. 130(1): p. 223-33. 42. Lagas, J.S., et al., Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res, 2009. 15(7): p. 2344-51. 43. Oostendorp, R.L., et al., The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs, 2009. 27(1): p. 31-40.